(Q36698173)

English

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy

scientific article published on 26 February 2013

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Clinical significance of CD33 nonsynonymous single-nucleotide polymorphisms in pediatric patients with acute myeloid leukemia treated with gemtuzumab-ozogamicin-containing chemotherapy (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

single-nucleotide polymorphism

1 reference

based on heuristic

inferred from title

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

author name string

Leslie Mortland

1

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Todd A Alonzo

2

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Roland B Walter

3

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Robert B Gerbing

4

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Amit K Mitra

5

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jessica A Pollard

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Michael R Loken

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Betsy Hirsch

8

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Susana Raimondi

9

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Janet Franklin

10

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Stanley Pounds

11

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Xueyuan Cao

12

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jeffrey E Rubnitz

13

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Raul C Ribeiro

14

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Alan Gamis

15

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Soheil Meshinchi

16

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Jatinder K Lamba

17

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

language of work or name

0 references

publication date

26 February 2013

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

19

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1620-1627

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

Coding polymorphisms in CD33 and response to gemtuzumab ozogamicin in pediatric patients with AML: a pilot study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

p75/AIRM1 and CD33, two sialoadhesin receptors that regulate the proliferation or the survival of normal and leukemic myeloid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

Monoclonal antibodies to the myeloid stem cells: therapeutic implications of CMA-676, a humanized anti-CD33 antibody calicheamicin conjugate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

30 September 2017

Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

28 June 2018

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

5 September 2018

Flow cytometric mean fluorescence intensity: the biophysics behind the number

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3602123

5 September 2018

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/23444229

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Treatment of AML: resurrection for gemtuzumab ozogamicin?

1 reference

https://pubmed.ncbi.nlm.nih.gov/23444229

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-12-3115

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36698173&oldid=2086502859"